Stem Cell Patch to Heal Damaged Hearts
November 11, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Posicor
(United States) [DSC]Synonyms :
mibefradil
Class :
Calcium Antagonists
Brand Name :
Posicor
(United States) [DSC]Synonyms :
mibefradil
Class :
Calcium Antagonists
Dosage forms and strengths Â
Oral TabletÂ
100 mgÂ
50 mgÂ
The starting oral dose is 50 mg one time daily
If necessary and well-tolerated, the dose may be gradually increased to orally intake of 100 mg daily for maintenance dose
The starting oral dose is 50 mg one time daily
If necessary and well-tolerated, the dose may be gradually increased to orally intake of 100 mg daily for maintenance dose
Not indicatedÂ
Refer adult dosingÂ
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may increase the hypotensive effect of alpha1-blockers
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
QT-prolonging Strong may enhance the QTc-prolonging effect of delamanid
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
may decrease the serum concentration of Quinolones
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
may enhance the QTc-prolonging effect of Fluorouracil Products
gilteritinib may enhance the QTc-prolonging effect of QT-prolonging Agents
may increase the serum concentration of colchicine
may enhance the Qtc prolonging effect
may increase the levels of serum concentration of ivacaftor/tezacaftor
may enhance the serum concentrations of active metabolites
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the serum concentration
may increase the serum concentration
may increase the QTc prolonging effect
may increase the QTc prolonging effect
may increase the hypotensive effect of anti-hypertensive agents
may increase the hypotensive effect of anti-hypertensive agents
may increase the bradycardic effect of bradycardia-causing agents
may enhance serum concentrations when combined with tetrabenazine
may increase the level of serum concentration of adagrasib
may enhance the serum concentration when combined with fenfluramine
may enhance the serum concentration when combined with fenfluramine
may diminish the serum concentration when combined with CYP2D6 substrates
may have an increased QTc-prolonging effect when combined with amisulpride (oral)
may decrease the therapeutic effect of each other when combined
may enhance the serum concentration
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may have an increased bradycardic effect when combined with fingolimod
may have an increased bradycardic effect when combined with ponesimod
may have an increased bradycardic effect when combined with siponimod
may increase the serum concentration of Rasagiline
may have an increased QTc-prolonging effect when combined with amiodarone
may have an increased QTc-prolonging effect when combined with arsenic trioxide
may have an increased QTc-prolonging effect when combined with astemizole
may have an increased QTc-prolonging effect when combined with bedaquiline
may have an increased QTc-prolonging effect when combined with chloroquine
may have an increased QTc-prolonging effect when combined with chlorpromazine
may have an increased QTc-prolonging effect when combined with cisapride
may have an increased QTc-prolonging effect when combined with clofazimine
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with clozapine
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with dasatinib
may have an increased QTc-prolonging effect when combined with delamanid
may have an increased QTc-prolonging effect when combined with doxepin-containing products
may increase the QTc-prolonging effect of QT-prolonging Agents
may have an increased bradycardic effect when combined with ceritinib
may have an increased bradycardic effect when combined with fingolimod
may have an increased bradycardic effect when combined with ponesimod
may have an increased bradycardic effect when combined with siponimod
may enhance the concentration of serum when combined with theophylline derivatives
may diminish the serum concentration of Voxelotor
may enhance the concentration of serum when combined with thioridazine
lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors
pirfenidone: they may enhance the serum concentration of CYP1A2 Inhibitors
pomalidomide: they may enhance the serum concentration of CYP1A2 Inhibitors
propranolol: they may enhance the serum concentration of CYP1A2 Inhibitors
sirolimus: they may enhance the serum concentration of CYP3A4 Inhibitors
budesonide: they may enhance the serum concentration of CYP3A4 Inhibitors
may increase the QTc-prolonging effect of each other when combined
May enhance the QTc-prolonging effect of each other when combined
dronedarone: they may increase the QTc-prolonging effect of QTc-prolonging miscellaneous agents
encorafenib: they may increase the QTc-prolonging effect of QTc-prolonging agents
escitalopram: they may increase the QTc-prolonging effect of QTc-prolonging Agents
etelcalcetide: they may increase the QTc-prolonging effect of QTc-prolonging agents
flecainide: they may increase the QTc-prolonging effect of QTc-prolonging Agents
fluconazole: they may increase the QTc-prolonging effect of QTc-prolonging agents
gilteritinib: they may increase the QTc-prolonging effect of QTc-prolonging agents
halofantrine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
imipramine: they may increase the QTc-prolonging effect of QTc-prolonging agents
inotuzumab: they may enhance the QTc-prolonging effect of QTc-prolonging agents
may increase the hypotensive effect of anti-hypertensive agents
lofexidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
midostaurin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
olanzapine: they may enhance the QTc-prolonging effect of QTc-prolonging Agents
osimertinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propafenone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propofol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
sunitinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
toremifene: they may increase the QTc-prolonging effect of QTc-prolonging Agents
vemurafenib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ripretinib: they may diminish the serum concentration of CYP3A4 Inducers
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may enhance the QTc-prolonging effect of each other when combined
may enhance the QTc-prolonging effect of each other when combined
alfentanil: they may enhance the serum concentration of CYP3A Inhibitors
avanafil: they may enhance the serum concentration of CYP3A Inhibitors
budesonide: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
cilostazol: they may enhance the serum concentration of CYP3A Inhibitors
cisapride: they may enhance the serum concentration of CYP3A Inhibitors
dapoxetine: they may enhance the serum concentration of CYP3A Inhibitors
daridorexant: they may enhance the serum concentration of CYP3A Inhibitors
eliglustat: they may enhance the serum concentration of CYP3A Inhibitors
encorafenib: they may enhance the serum concentration of CYP3A Inhibitors
eplerenone: they may enhance the serum concentration of CYP3A Inhibitors
fentanyl: they may enhance the serum concentration of CYP3A Inhibitors
ivacaftor: they may enhance the serum concentration of CYP3A Inhibitors
lumateperone: they may enhance the serum concentration of CYP3A Inhibitors
mitapivat: they may enhance the serum concentration of CYP3A Inhibitors
naloxegol: they may enhance the serum concentration of CYP3A Inhibitors
omaveloxolone: they may enhance the serum concentration of CYP3A Inhibitors
pexidartinib: they may enhance the serum concentration of CYP3A Inhibitors
rimegepant: they may enhance the serum concentration of CYP3A Inhibitors
suvorexant: they may enhance the serum concentration of CYP3A Inhibitors
tolvaptan: they may enhance the serum concentration of CYP3A Inhibitors
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
arginine: they may enhance the serum concentration of CYP2D6 Inhibitors
nicardipine: they may enhance the serum concentration of CYP2D6 Inhibitors
brimonidine: they may enhance the serum concentration of CYP2D6 Inhibitors
cimetidine: they may enhance the serum concentration of CYP2D6 Inhibitors
clopidogrel: they may enhance the serum concentration of CYP2D6 Inhibitors
dapoxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
diazoxide: they may enhance the serum concentration of CYP2D6 Inhibitors
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
ceritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
afatinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
pilsicainide HCL: they may increase the QTc-prolonging effect of QTc-prolonging Agents
clozapine: they may increase the bradycardic effect of Bradycardia-Causing Agents
secretin: they may increase the bradycardic effect of Bradycardia-Causing Agents
sincalide: they may increase the bradycardic effect of Bradycardia-Causing Agents
aclidinium: they may increase the bradycardic effect of Bradycardia-Causing Agents
cimetropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
eluxadoline: they may increase the bradycardic effect of Bradycardia-Causing Agents
glycopyrrolate: they may increase the bradycardic effect of Bradycardia-Causing Agents
ipratropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
levosulpiride: they may increase the bradycardic effect of Bradycardia-Causing Agents
atropine: they may increase the bradycardic effect of Bradycardia-Causing Agents
oxatomide: they may increase the bradycardic effect of Bradycardia-Causing Agents
potassium chloride: they may increase the bradycardic effect of Bradycardia-Causing Agents
revefenacin: they may increase the bradycardic effect of Bradycardia-Causing Agents
tiotropium: they may increase the bradycardic effect of Bradycardia-Causing Agents
umeclidinium: they may increase the bradycardic effect of Bradycardia-Causing Agents
aripiprazole lauroxil: they may enhance the serum concentration of CYP2D6 Inhibitors
brexpiprazole: they may enhance the serum concentration of CYP2D6 Inhibitors
lemborexant: they may enhance the serum concentration of CYP2D6 Inhibitors
pitolisant: they may enhance the serum concentration of CYP2D6 Inhibitors
ubrogepant: they may enhance the serum concentration of CYP2D6 Inhibitors
caplacizumab: they may enhance the serum concentration of CYP2D6 Inhibitors
cilostazol: they may enhance the serum concentration of CYP2D6 Inhibitors
eliglustat: they may enhance the serum concentration of CYP2D6 Inhibitors
dextroamphetamine: they may enhance the serum concentration of CYP2D6 Inhibitors
enoxaparin: they may enhance the serum concentration of CYP2D6 Inhibitors
gilteritinib: they may enhance the serum concentration of CYP2D6 Inhibitors
fluoxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
oxycodone: they may enhance the serum concentration of CYP2D6 Inhibitors
lomitamide: they may enhance the serum concentration of CYP2D6 Inhibitors
safinamide: they may enhance the serum concentration of CYP2D6 Inhibitors
aclidinium: they may enhance the serum concentration of CYP3A Inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
calcium chloride: it may increase the risk or severity of QTc prolongation
calcium gluconate: it may increase the risk or severity of QTc prolongation
dapagliflozin: it may increase the risk or severity of QTc prolongation
darunavir: it may increase the risk or severity of QTc prolongation
alprazolam: it may increase the risk or severity of QTc prolongation
cinnarizine and dimenhydrinateÂ
this is combination is contraindicated in patients with cardiovascular diosrdrs who are on antiarrhythmic drugs
betony along with antihypertensive drugs can lower blood pressure abruptly which is contraindicated
bloodroot along with antihypertensive medications will result in amplified hypotensive effect
bloodroot along with anti-arrhythmic medications will result in irregularity in heartbeat and bradycardia
deferiprone: it may increase the bradycardic effect of Bradycardia-Causing Agents
thalidomide: it may increase the bradycardic effect of Bradycardia-Causing Agents
dexamethasone: it may increase the bradycardic effect of Bradycardia-Causing Agents
azelastine: it may increase the bradycardic effect of Bradycardia-Causing Agents
carbinoxamine: it may increase the risk of QTc prolongation agents
capsaicin: it may increase the risk of QTc prolongation agents
benzydamine: it may increase the risk of QTc prolongation agents
rosoxacin: it may increase the risk of QTc prolongation agents
may enhance the antihypertensive effect of other alpha1-Blockers
bunazosin (Not available in the United States)
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may have an increased hyperkalemic effect when combined with spironolactone
may have an increased hyperkalemic effect when combined with spironolactone
may have an increased hyperkalemic effect when combined with spironolactone
it may enhance the QTc-prolonging effect of terfenadine
may enhance the QTc-prolonging effect of Nilotinib
it decreases the effect of hypotension on blood-lowering agents
CYP2D6 inhibitors increase the concentration of aripiprazole in the serum
they decrease the concentration of active metabolites of roflumilast in the serum
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of CYP3A4 substrates in serum
may increase the levels of serum concentration of eletriptan
they increase the concentration of alosetron in the serum
bradycardia causing agents increase the arrhythmia-causing effect of fexinidazole
may increase the Qtc prolonging effect
may enhance the serum concentration
may increase the hypotensive effect of anti-hypertensive agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
may have an increased hyperkalemic effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
bunazosin (Not available in the United States)
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
they decrease the concentration of active metabolites of infigratinib in the serum
CYP3A4 inhibitors increase the concentration of pimozide in the serum
they decrease the concentration of active metabolites of iloperidone in the serum
may enhance the serum concentration of tafamidis
May enhance the hyperkalemic effect when combined with Calcium Channel Blockers
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with flupentixol
may have an increased QTc-prolonging effect when combined with nilotinib
may have an increased QTc-prolonging effect when combined with pazopanib
may enhance the serum concentration when combined
may decrease the therapeutic effect when combined with etofylline
they decrease the concentration of lurbinectedin in the serum
QT-prolonging agents (Highest Risk) may increase clarithromycin's ability to prolong QTc
May increase the QTc-prolonging effect of QT-prolonging Agents
may increase the QTc-prolonging effect of QT-prolonging Agents
may diminish the concentration of serum when combined with CYP1A2 substrates
agomelatine: they may enhance the serum concentration of CYP1A2 Inhibitors
duloxetine: they may enhance the serum concentration of CYP1A2 Inhibitors
melatonin: they may enhance the serum concentration of CYP1A2 Inhibitors
mexiletine: they may enhance the serum concentration of CYP1A2 Inhibitors
ramelteon: they may enhance the serum concentration of CYP1A2 Inhibitors
tasimelteon: they may enhance the serum concentration of CYP1A2 Inhibitors
thiazide and it’s like diuretics increase the effect of QTc prolongation
May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics
may increase the serum concentration of each other when combined
may increase the hypertensive effect when combined with androgens
piperaquine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
probucol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
quetiapine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
sparfloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
thioridazine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
fexinidazole: they may enhance the serum concentration of CYP3A4 inhibitors
fusidic acid: they may enhance the serum concentration of CYP3A inhibitors
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
trabectedin: they may diminish the serum concentration of CYP3A Inhibitors
aprepitant: they may enhance the serum concentration of CYP3A Inhibitors
asunaprevir: they may enhance the serum concentration of CYP3A Inhibitors
bosutinib: they may enhance the serum concentration of CYP3A Inhibitors
domperidone: they may enhance the serum concentration of CYP3A Inhibitors
elacestrant: they may enhance the serum concentration of CYP3A Inhibitors
fosaprepitant: they may enhance the serum concentration of CYP3A Inhibitors
ivabradine: they may enhance the serum concentration of CYP3A Inhibitors
lemborexant: they may enhance the serum concentration of CYP3A Inhibitors
lomitapide: they may enhance the serum concentration of CYP3A Inhibitors
methysergide: they may enhance the serum concentration of CYP3A Inhibitors
pacritinib: they may enhance the serum concentration of CYP3A Inhibitors
sertindole: they may enhance the serum concentration of CYP3A Inhibitors
simeprevir: they may enhance the serum concentration of CYP3A Inhibitors
sincalide: they may enhance the serum concentration of CYP2D6 Inhibitors
obinutuzumab: they may enhance the serum concentration of CYP2D6 Inhibitors
doxorubicin: they may enhance the serum concentration of CYP2D6 Inhibitors
pimozide: they may enhance the serum concentration of CYP2D6 Inhibitors
aclidinium: they may enhance the serum concentration of CYP2D6 Inhibitors
bromopride: they may enhance the serum concentration of CYP2D6 Inhibitors
cimetropium: they may enhance the serum concentration of CYP2D6 Inhibitors
glycopyrrolate: they may enhance the serum concentration of CYP2D6 Inhibitors
ipratropium: they may enhance the serum concentration of CYP2D6 Inhibitors
levosulpiride: they may enhance the serum concentration of CYP2D6 Inhibitors
mavacamten: they may enhance the serum concentration of CYP2D6 Inhibitors
olopatadine: they may enhance the serum concentration of CYP2D6 Inhibitors
rasagiline: they may enhance the serum concentration of CYP2D6 Inhibitors
selegiline: they may enhance the serum concentration of CYP2D6 Inhibitors
amoxicillin: it may increase the risk of QTc prolongation agents
anagrelide: it may increase the risk of QTc prolongation agents
antipyrine: it may increase the risk of QTc prolongation agents
benzthiazide: it may increase the risk of adverse effects with CYP3A inhibitors
betaine: it may increase the risk of adverse effects with CYP3A inhibitors
carboplatin: it may increase the risk of adverse effects with CYP3A inhibitors
carfilzomib: it may increase the risk of adverse effects with CYP3A inhibitors
dactinomycin: it may increase the risk of adverse effects with CYP3A inhibitors
dapagliflozin: it may increase the risk of adverse effects with CYP3A inhibitors
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
may enhance the hypotensive effect of calcium channel blockers
bunazosin (Not available in the United States)
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
bazedoxifene/conjugated estrogens
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
synthetic conjugated estrogens, a
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
synthetic conjugated estrogens, b
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
relugolix/​estradiol/​norethindrone
may enhance the hypertensive effect of Androgens
relugolix/estradiol/norethindrone
may enhance the hypertensive effect of Androgens
may enhance the hypertensive effect of Androgens
may enhance the hypertensive effect of Androgens
may enhance the hypertensive effect of Androgens
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antihypertensive agents
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
may increase the serum concentration
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may increase the levels of serum concentration
may increase the levels of serum concentration
They may increase the hypotensive effect when combined with antihypertensive agents
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
may have an increased hypertensive effect when combined with androgens
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of anti-parkinsonism drugs
may increase the hypotensive effect of alpha1-blockers
bunazosin (Not available in the United States)
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may decrease the therapeutic effect of calcium salts
may decrease the therapeutic effect of calcium salts
may decrease the therapeutic effect of calcium salts
may decrease the therapeutic effect of calcium salts
may decrease the therapeutic effect of calcium salts
may have an increased bradycardic effect when combined with other bradycardia-causing agents
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may enhance the serum concentration
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
bunazosin (Not available in the United States)
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may increase the hypotensive effect of alpha1-blockers
may have an increased QTc-prolonged effect when combined with chloroquine
may have an increased QTc-prolonged effect when combined with chloroquine
there is a additive effect when beta- antiarrhythmics are combined with antiglaucoma agents
systemic beta blockade is shown when CYP2D6 inhibtors are combined in use with antiglaucoma agents
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
QT-prolonging Agents may enhance the QTc-prolonging effect of haloperidol
it may enhance the QTc-prolonging effect of levoketoconazole
alfuzosin may enhance the hypotensive effect of Blood Pressure Lowering Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
fingolimod may enhance the QTc-prolonging effect of QT-prolonging Agents
fexinidazole may enhance the QTc-prolonging effect of QT-prolonging Agents
may enhance the QTc-prolonging effect of Moxifloxacin
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the adverse/toxic effect of lacosamide
it decreases the efficacy of antihypertensive agents
it decreases the efficacy of antihypertensive agents
it decreases the efficacy of antihypertensive agents
antihypertensive agents increase the efficacy of antipsychotic agents
it decreases the efficacy of antihypertensive agents
antihypertensive agents include the efficacy of duloxetine
it increases the efficacy of antihypertensive agents
it decreases the efficacy of antihypertensive agents
antihypertensive agents increase the efficacy of nitroprusside
calcium salts reduce the efficacy of calcium channel blockers
calcium salts reduce the efficacy of calcium channel blockers
calcium salts reduce the efficacy of calcium channel blockers
calcium salts reduce the efficacy of calcium channel blockers
calcium salts reduce the efficacy of calcium channel blockers
may increase the hypotensive effect
may enhance the serum concentration
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may increase the hypotensive effect
may enhance the Qtc prolonging effect
may enhance the Qtc prolonging effect
may enhance the serum concentration
may enhance the QTc-prolonging effect of haloperidol
it increases the concentration of CYP3A4 substrates in the serum
they decrease the concentration of active metabolites of roflumilast in the serum
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
may increase the serum concentration
hydrocodone/​chlorpheniramine/​pseudoephedrineÂ
may diminish the serum concentration
it increases the concentration of alosetron in the serum
they decrease the concentration of linagliptin in the serum
may enhance the serum concentration
may increase the serum concentration of clozapine
may increase the levels of serum concentrations of cariprazine
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
bradycardia-causing agents increase the efficacy of ivabradine
may enhance the serum concentration
may increase the serum concentration
may increase the serum concentration of CYP3A4 substrates
may increase the hypertensive effect
may increase the hypotensive effect
QTc-prolongers increase the effect of levoketoconazole
azelastine/fluticasone intranasalÂ
may enhance the serum concentration
may increase the hypoglycaemic effect
may enhance the serum concentration of macitentan
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the antiarrhythmic effect
may increase the serum concentration of abemaciclib
may increase the serum concentration
may increase the antiplatelet effect of antiplatelet agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may reduce the effect of antihypertensive drugs
may reduce the effect of antihypertensive drugs
may reduce the effect of antihypertensive drugs
may reduce the effect of antihypertensive drugs
may reduce the effect of antihypertensive drugs
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may increase the hypotensive effect of anti-hypertensive agents
may increase the QTc prolonging effect of QTc prolonging agents
may increase the serum concentration
may increase the bradycardic effect of bradycardia-causing agents
may decrease the hypertensive effect of amphetamines
may increase the serum concentration of amphetamines
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may decrease the antihypertensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased adverse effect when combined with atosiban
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the therapeutic effect when combined with calcium channel blockers
may decrease the therapeutic effect when combined with calcium channel blockers
may decrease the therapeutic effect when combined with calcium channel blockers
may decrease the therapeutic effect when combined with calcium channel blockers
may decrease the therapeutic effect when combined with calcium channel blockers
may enhance the serum concentration when combined with calcium channel blockers
may decrease the therapeutic effect when combined with clopidogrel
may enhance the serum concentration when combined with cyclosporine
may have an increased orthostatic hypotensive effect when combined with calcium channel blockers
may decrease the therapeutic effect when combined with antihypertensive agents
may enhance the serum concentration when combined with CYP2D6 substrates
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
may enhance the serum concentrations of CYP2D6 inhibitors
may increase the level of serum concentration of itraconazole
CYP3A4 inhibitors increase the concentration of carbamazepine in the serum
CYP3A4 inhibitors increase the concentration of iloperidone in the serum
relugolix/​estradiol/​norethindrone
may have an increased hypertensive effect when combined with Androgens
relugolix/estradiol/norethindrone
may have an increased hypertensive effect when combined with Androgens
may have an increased hypertensive effect when combined with Androgens
may have an increased hypertensive effect when combined with Androgens
may have an increased hypertensive effect when combined with Androgens
may have an increased hypotensive effect when combined with duloxetine
may increase the QTc prolonging effect of QT-prolonging agents
may enhance the bradycardic effect of bradycardia-causing agents
CYP3A4 inhibitors increase the concentration of rivaroxaban
may increase the hypotensive effect of barbiturates
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with levodopa-containing products
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with nitroprusside
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with pholcodine
may increase the hypotensive effect of blood pressure lowering agents
may increase the hypotensive effect of blood pressure lowering agents
may increase the hypoglycemic effect of Antidiabetic Agents
may increase the adverse effect of Antiarrhythmic Agents
may diminish the serum concentration of Lidocaine
may increase the serum concentration of Lidocaine
may have an increasingly adverse effect when combined with antiarrhythmic agents (class Ib)
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antihypertensive agents
may increase the hypotensive effect of Hypotension-Associated Agents
promethazine/dextromethorphanÂ
may increase the serum concentration of Dextromethorphan
may increase the levels of serum concentration of pimavanserin
may have an increased hypertensive effect when combined with hypertension agents
may increase the levels of serum concentration
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
It may increase the hypotensive effect when combined with Antihypertensive Agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may increase the hypotensive effect of Hypotension-Associated Agents
may increase the hypotensive effect of Inhalational Anaesthetics
may increase the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased therapeutic effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the hypotensive effect of Antipsychotic Agents
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may enhance the concentration of serum when combined with timolol
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration
synthetic conjugated estrogens, a
may increase the levels of serum concentration
synthetic conjugated estrogens, b
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
estrogens esterified/methyltestosterone            Â
may enhance the hypertensive effect of androgens
clozapine: they may enhance the serum concentration of CYP1A2 Inhibitors
It may enhance the serum concentration when combined with CYP3A4 Inhibitors
They may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
may enhance the concentration of serum when combined with asenapine
acetaminophen/doxylamine/dextromethorphanÂ
may enhance the serum concentration when combined
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
may enhance the serum concentration of cyclosporine
may enhance the serum concentration of Vitamin D Analogs
antihypertensive drugs may make terazosin's hypotensive effects worse
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increasingly adverse effect when combined with atosiban
may increase the levels of serum concentration
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased bradycardic effect when combined with ivabradine
anagrelide: they may enhance serum concentrations of CYP1A2 Inhibitors
bromazepam: they may enhance the serum concentration of CYP1A2 Inhibitors
clomipramine: they may enhance the serum concentration of CYP1A2 Inhibitors
flibanserin: they may enhance the serum concentration of CYP3A Inhibitors
dofetilide: they may enhance the serum concentration of CYP3A Inhibitors
finerenone: they may enhance the serum concentration of CYP3A Inhibitors
ixabepilone: they may enhance the serum concentration of CYP3A Inhibitors
levobupivacaine: they may enhance the serum concentration of CYP1A2 Inhibitors
lidocaine: they may enhance the serum concentration of CYP1A2 Inhibitors
nimodipine: they may enhance the serum concentration of CYP3A Inhibitors
olanzapine: they may enhance the serum concentration of CYP1A2 Inhibitors
pentoxifylline: they may enhance the serum concentration of CYP1A2 Inhibitors
ramosetron: they may enhance the serum concentration of CYP1A2 Inhibitors
riluzole: they may enhance the serum concentration of CYP1A2 Inhibitors
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
ropinirole: they may enhance the serum concentration of CYP1A2 Inhibitors
ropivacaine: they may enhance the serum concentration of CYP1A2 Inhibitors
fusidic acid and betamethasoneÂ
may enhance the serum concentration when combined
may increase the bradycardic effect of each other
may have an increased QTc-prolonging effect when combined with gadobenate dimeglumine
prazosin: they may increase the hypotensive effect when combined with antihypertensive agents
may increase the QTc-prolonging effect when combined
may increase the hypotensive effect of Phosphodiesterase 5 Inhibitors
may increase the hypotensive effect of Hypotension-Associated Agents
may increase the QTc-prolonging effect of each other when combined
abametapir with mibefradil may result in an enhance in the concentration serum of mibefradil
The serum concentration of abemaciclib can be elevated when used together with mibefradil
The combination of mibefradil and abrocitinib can lead to an increase in the concentration serum of mibefradil
acalabrutinib is combined with mibefradil, there is a possibility of an enhanced concentration serum of acalabrutinib
Combining mibefradil with acarbose can elevate the risk or seriousness of hypoglycemia
acebutolol has the potential to enhance the arrhythmogenic effects of mibefradil
The combination of mibefradil and acenocoumarol might lead to an enhance in the concentration serum of acenocoumarol
may diminish the effect of antihypertensive activity
may diminish the effect of antihypertensive activity
may diminish the effect of antihypertensive activity
may diminish the effect of antihypertensive activity
may diminish the effect of antihypertensive activity
CYP2D6 Inhibitors: they may enhance the serum concentration of nebivolol
midodrine: they may increase the bradycardic effect of Bradycardia-Causing Agents
ozanimod: they may increase the bradycardic effect of Bradycardia-Causing Agents
tofacitinib: they may increase the bradycardic effect of Bradycardia-Causing Agents
may have an increased QTc-prolonging effect when combined with fluorouracil products
may have an increased QTc-prolonging effect when combined with pentamidine
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
it may diminish the excretion rate when combined with Growth hormone agonist, resulting in an enhanced serum level
may decrease the hypotensive effect of Blood Pressure Lowering Agents
may enhance the QTc-prolonging effect of each other when combined
they decrease the efficacy of calcium channel blockers
they decrease the efficacy of calcium channel blockers
they decrease the efficacy of calcium channel blockers
they decrease the efficacy of calcium channel blockers
they decrease the efficacy of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
it increases the toxicity of calcium channel blockers
it increases the toxicity of calcium channel blockers cabergoline
When asciminib is combined with mibefradil, there is a potential for an increase in the concentration serum of mibefradil
The potential for hyperkalemia to occur may be enhanced when amiloride is used concurrently with mibefradil
The effectiveness of mibefradil may be diminished when utilized concurrently with aminophenazone
The combination of mibefradil can lead to an elevation in the concentration serum of aminophylline
when amiodarone is used in conjunction with mibefradil, The risk or seriousness of adverse events may be enhanced
The potential for QTc prolongation's risk or seriousness may escalate with the concomitant use of mibefradil and amisulpride
hydroxyzine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
pacritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
clofazimine: they may enhance the serum concentration of CYP3A inhibitors
mometasone (Nasal): they may enhance the serum concentration of CYP3A Inhibitors
may decrease the serum concentration when combined with CYP1A2 substrates
may decrease the serum concentration when combined with CYP1A2 substrates
they decrease the efficacy of calcium channel blockers
they decrease the efficacy of calcium channel blockers
they decrease the efficacy of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
inhalational anesthetics increase the effect of hypotension of calcium channel blockers
pilsicainide hydrochloride increases the risk of arrhythmia when co-administered with other anti-arrhythmic agents
oxaceprol decreases the effect of anti-hypertensives
It may enhance the risk of adverse effects when combined with Androgens
It may enhance the risk of adverse effects when combined with Androgens
alfuzosin: they may enhance the serum concentration of CYP3A Inhibitors
alitretinoin: they may enhance the serum concentration of CYP3A Inhibitors
amiodarone: they may enhance the serum concentration of CYP3A Inhibitors
amlodipine: they may enhance the serum concentration of CYP3A Inhibitors
atorvastatin: they may enhance the serum concentration of CYP3A Inhibitors
axitinib: they may enhance the serum concentration of CYP3A Inhibitors
barnidipine: they may enhance the serum concentration of CYP3A Inhibitors
bedaquiline: they may enhance serum concentrations of CYP3A Inhibitors
It may enhance the risk of adverse effects when combined with CYP1A2 inhibitors
It may enhance the risk of adverse effects when combined with CYP1A2 inhibitors
It may enhance the risk of adverse effects when combined with CYP1A2 inhibitors
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
benidipine: they may enhance the serum concentration of CYP3A Inhibitors
buprenorphine: they may enhance the serum concentration of CYP3A Inhibitors
cabozantinib: they may enhance the serum concentration of CYP3A Inhibitors
clozapine: they may enhance the serum concentration of CYP3A Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A Inhibitors
isavuconazonium sulfate: they may diminish serum concentrations of CYP3A Inhibitors
darifenacin: they may enhance the serum concentration of CYP3A Inhibitors
ebastine: they may enhance the serum concentration of CYP3A Inhibitors
eszopiclone: they may enhance the serum concentration of CYP3A inhibitors
fedratinib: they may enhance the serum concentration of CYP3A inhibitors
felodipine: they may enhance the serum concentration of CYP3A inhibitors
gilteritinib: they may enhance the serum concentration of CYP3A inhibitors
lapatinib: they may enhance the serum concentration of CYP3A inhibitors
manidipine: they may enhance the serum concentration of CYP3A Inhibitors
salmeterol: they may enhance the serum concentration of CYP3A Inhibitors
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
It may enhance the risk of adverse effects when combined with antianginal drugs
amitriptyline: they may enhance the serum concentration of CYP2D6 Inhibitors
amoxapine: they may enhance the serum concentration of CYP2D6 Inhibitors
amphetamine: they may enhance the serum concentration of CYP2D6 Inhibitors
atomoxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
bupropion: they may enhance the serum concentration of CYP2D6 Inhibitors
carvedilol: they may enhance the serum concentration of CYP2D6 Inhibitors
celiprolol: they may enhance the serum concentration of CYP2D6 Inhibitors
clomipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
clozapine: they may enhance the serum concentration of CYP2D6 Inhibitors
codeine: they may enhance the serum concentration of CYP2D6 Inhibitors
rolapitant: they may enhance the serum concentration of CYP2D6 Inhibitors
desipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
deutetrabenazine: they may enhance the serum concentration of CYP2D6 Inhibitors
doxepin: they may enhance the serum concentration of CYP2D6 Inhibitors
flecainide: they may enhance the serum concentration of CYP2D6 Inhibitors
imipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
oliceridine: they may enhance the serum concentration of CYP2D6 Inhibitors
propafenone: they may enhance the serum concentration of CYP2D6 Inhibitors
propranolol: they may enhance the serum concentration of CYP2D6 Inhibitors
protriptyline: they may enhance the serum concentration of CYP2D6 Inhibitors
tamsulosin: they may enhance the serum concentration of CYP2D6 Inhibitors
tramadol: they may enhance the serum concentration of CYP2D6 Inhibitors
valbenazine: they may enhance the serum concentration of CYP2D6 Inhibitors
vortioxetine: they may enhance the serum concentration of CYP2D6 Inhibitors
zuclopenthixol: they may enhance the serum concentration of CYP2D6 Inhibitors
molsidomine: they may decrease the antihypertensive effect of antihypertensive agents
nicergoline: they may decrease the antihypertensive effect of antihypertensive agents
hydralazine: they may decrease the antihypertensive effect of antihypertensive agents
amifostine: they may enhance the serum concentration of CYP2D6 Inhibitors
flunarizine: they may enhance the serum concentration of CYP2D6 Inhibitors
melatonin: they may enhance the serum concentration of CYP2D6 Inhibitors
molsidomine: they may enhance the serum concentration of CYP2D6 Inhibitors
dimercaprol: they may enhance the serum concentration of CYP2D6 Inhibitors
levonorgestrel: they may enhance the serum concentration of CYP2D6 Inhibitors
may increase the hypotensive effect of blood pressure lowering agents
may increase the hypotensive effect of blood pressure lowering agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may have an increased bradycardic effect when combined with other bradycardia-causing agents
quinagolide: they may increase the hypotensive effect of antihypertensive agents
adverse effects or toxic effects of lacosamide are increased by antiarrhythmic agents when used in combination
amifampridine: they may increase the bradycardic effect of Bradycardia-Causing Agents
dipyridamole: they may increase the bradycardic effect of Bradycardia-Causing Agents
mirabegron: they may increase the bradycardic effect of Bradycardia-Causing Agents
nitroglycerin: they may increase the bradycardic effect of Bradycardia-Causing Agents
succinylcholine: they may increase the bradycardic effect of Bradycardia-Causing Agents
topiramate: they may increase the bradycardic effect of Bradycardia-Causing Agents
fluorouracil: they may increase the bradycardic effect of Bradycardia-Causing Agents
methoxsalen: they may increase the bradycardic effect of Bradycardia-Causing Agents
porfimer: they may increase the bradycardic effect of Bradycardia-Causing Agents
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
bunazosin (Not available in the United States)
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with anti-hypertensive agents
quinidine: they may enhance the serum concentration of CYP2D6 Inhibitors
butchers broom: they may enhance the serum concentration of CYP2D6 Inhibitors
finerenone: they may enhance the serum concentration of CYP2D6 Inhibitors
alprazolam: they may enhance the serum concentration of CYP2D6 Inhibitors
ephedrine: they may enhance the serum concentration of CYP2D6 Inhibitors
kaolin: they may enhance the serum concentration of CYP2D6 Inhibitors
verteporfin: they may enhance the serum concentration of CYP2D6 Inhibitors
trimipramine: they may enhance the serum concentration of CYP2D6 Inhibitors
vitamin K1: they may enhance the serum concentration of CYP2D6 Inhibitors
triazolam: they may enhance the serum concentration of CYP2D6 Inhibitors
alvimopan: they may enhance the serum concentration of CYP2D6 Inhibitors
chlormethiazole: they may enhance the serum concentration of CYP2D6 Inhibitors
flunitrazepam: they may enhance the serum concentration of CYP2D6 Inhibitors
nalmefene: they may enhance the serum concentration of CYP2D6 Inhibitors
suvorexant: they may enhance the serum concentration of CYP2D6 Inhibitors
zolpidem: they may enhance the serum concentration of CYP2D6 Inhibitors
opioid drugs: they may enhance the serum concentration of CYP2D6 Inhibitors
opioid drugs: they may enhance the serum concentration of CYP2D6 Inhibitors
opioid drugs: they may enhance the serum concentration of CYP2D6 Inhibitors
opioid drugs: they may enhance the serum concentration of CYP2D6 Inhibitors
samidorphan: they may enhance the serum concentration of CYP2D6 Inhibitors
naltrexone: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
monoamine oxidase inhibitor: they may enhance the serum concentration of CYP2D6 Inhibitors
thalidomide: they may enhance the serum concentration of CYP2D6 Inhibitors
alizapride: they may enhance the serum concentration of CYP2D6 Inhibitors
kava: they may enhance the serum concentration of CYP2D6 Inhibitors
metyrosine: they may enhance the serum concentration of CYP2D6 Inhibitors
piribedil: they may enhance the serum concentration of CYP2D6 Inhibitors
anagrelide: they may enhance the serum concentration of CYP2D6 Inhibitors
belzutifan: they may enhance the serum concentration of CYP2D6 Inhibitors
cannabis: they may enhance the serum concentration of CYP2D6 Inhibitors
dasatinib: they may enhance the serum concentration of CYP2D6 Inhibitors
etravirine: they may enhance the serum concentration of CYP2D6 Inhibitors
inotersen: they may enhance the serum concentration of CYP2D6 Inhibitors
lithium: they may enhance the serum concentration of CYP2D6 Inhibitors
metoprolol: they may enhance the serum concentration of CYP2D6 Inhibitors
nifedipine: they may enhance the serum concentration of CYP2D6 Inhibitors
omeprazole: they may enhance the serum concentration of CYP2D6 Inhibitors
perampanel: they may enhance the serum concentration of CYP2D6 Inhibitors
quetiapine: they may enhance the serum concentration of CYP2D6 Inhibitors
ramosetron: they may enhance the serum concentration of CYP2D6 Inhibitors
quinagolide: they may enhance the serum concentration of CYP2D6 Inhibitors
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
an increased risk of hypotension may be seen
moxonidine: it may decrease activities of antihypertensive drugs
ambrisentan: it may decrease activities of antihypertensive drugs
balsalazide: it may decrease activities of antihypertensive drugs
benorilate: it may decrease activities of antihypertensive drugs
benoxaprofen: it may decrease activities of antihypertensive drugs
carvedilol: it may decrease activities of antihypertensive drugs
chlorothiazide: it may decrease activities of antihypertensive drugs
celecoxib: it may decrease activities of antihypertensive drugs
chlorpromazine: it may decrease activities of antihypertensive drugs
amitriptyline: it may decrease activities of antihypertensive drugs
rimiterol: it may decrease activities of antihypertensive drugs
amlodipine: it may decrease activities of antihypertensive drugs
amoxapine: it may decrease activities of antihypertensive drugs
anagrelide: it may decrease activities of antihypertensive drugs
bisoprolol: it may decrease activities of antihypertensive drugs
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
cetirizine: it may increase the risk or severity of QTc prolongation
atropine: it may increase the risk or severity of QTc prolongation
azatadine: it may increase the risk or severity of QTc prolongation
calcium acetate: it may increase the risk or severity of QTc prolongation
gallopamil: it may increase the risk or severity of QTc prolongation
certoparin: it may increase the risk or severity of QTc prolongation
spironolactone and hydrochlorothiazide
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
may increase the hypotensive effect of antipsychotic agents
induction of these enzymes is shown by bupleurum at high doses
amitriptyline: it may increase the risk or severity of QTc prolongation agents
berotralstat: it may increase the risk or severity of QTc prolongation agents
betahistine: it may increase the risk or severity of QTc prolongation agents
acrivastine: it may increase the risk or severity of QTc prolongation agents
bilastine: it may increase the risk or severity of QTc prolongation agents
bisoprolol: it may increase the risk or severity of QTc prolongation agents
bisoxatin: it may increase the risk or severity of QTc prolongation agents
amikacin: it may increase the risk or severity of QTc prolongation agents
sulfamethoxazole: it may increase the risk or severity of QTc prolongation agents
benazepril: it may increase the risk or severity of QTc prolongation agents
bendamustine: it may increase the risk or severity of QTc prolongation agents
benorilate: it may increase the risk or severity of QTc prolongation agents
benoxaprofen: it may increase the risk or severity of QTc prolongation agents
benserazide: it may increase the risk or severity of QTc prolongation agents
cabergoline: it may increase the risk or severity of QTc prolongation agents
cabozantinib: it may increase the risk or severity of QTc prolongation agents
canagliflozin: it may increase the risk or severity of QTc prolongation agents
candesartan cilexetil: it may increase the risk or severity of QTc prolongation agents
pamidronate: it may enhance the bradycardic effect of Bradycardia-Causing Agents
valerian: it may enhance the bradycardic effect of Bradycardia-Causing Agents
zoledronic acid: it may enhance the bradycardic effect of Bradycardia-Causing Agents
relebactam: it may decrease the excretion of CYP3A inhibitors
cabotegravir: it may decrease the excretion of CYP3A inhibitors
capmatinib: it may decrease the excretion of CYP3A inhibitors
cefaclor: it may decrease the excretion of CYP3A inhibitors
cefalotin: it may decrease the excretion of CYP3A inhibitors
bumetanide: it may decrease the excretion of CYP3A inhibitors
diclofenac: it may decrease the excretion of CYP3A inhibitors
dolutegravir: it may decrease the excretion of CYP3A inhibitors
emtricitabine: it may decrease the excretion of CYP3A inhibitors
it may decrease the excretion of CYP3A inhibitors
ketoprofen: it may decrease the excretion of CYP3A inhibitors
fluprednisolone: it may increase the risk of adverse effects with CYP3A inhibitors
it may enhance the QTc-prolonging effect
it may enhance the QTc-prolonging effect
it may enhance the QTc-prolonging effect
it may enhance the QTc-prolonging effect
it may enhance the QTc-prolonging effect
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of glasdegib in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
CYP3A4 inhibitors increase the concentration of ubrogepant in the serum
they increase the concentration of metoclopramide in the serum
they modify the response of glucose or insulin when taken with manidipine
they decrease the concentration of active metabolites of tamoxifen in serum
Actions and Spectrum:Â
Action: mibefradil selectively blocks T-type calcium channels in the heart and peripheral blood vessels. Doing so reduces the influx of calcium ions into these cells, leading to vasodilation (widening of blood vessels) and decreased cardiac contractility. The net effect is a reduction in blood pressure and a decrease in the workload on the heart, making it an effective antihypertensive and antianginal agent.Â
Spectrum: mibefradil was initially approved to treat hypertension and chronic stable angina. Its unique mechanism of action, particularly its inhibition of T-type calcium channels, made it a promising alternative to other calcium channel blockers.Â
Â
Â
Frequency not defined Â
DyspepsiaÂ
Light-headednessÂ
Abdominal painÂ
RhinitisÂ
Leg edemaÂ
headacheÂ
Black Box Warning:Â Â
None Â
Contraindication/Caution:Â Â
Hypersensitivity: Individuals with a known hypersensitivity or allergy to mibefradil should not use this medication.Â
Concomitant Use with CYP3A4 Inhibitors: mibefradil was known to interact with CYP3A4 inhibitors, such as certain antifungal medications, certain antibiotics, and some HIV protease inhibitors, which could lead to potentially serious adverse effects. Therefore, co-administration with these inhibitors was contraindicated.Â
Liver Impairment: mibefradil was known to cause hepatotoxicity (liver toxicity) in some cases, and it was contraindicated in patients with pre-existing liver impairment or liver disease.Â
Hypotension: Since mibefradil was a calcium channel blocker, it could potentially cause low blood pressure (hypotension), especially in individuals with already low blood pressure or certain medical conditions.Â
Pregnancy warnings:    Â
Pregnancy category: CÂ
Lactation: Excreted into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â Â
mibefradil is a calcium channel blocker that was used to treat chronic stable angina pectoris and hypertension.Â
Pharmacodynamics:Â Â
mibefradil inhibits the influx of calcium ions through T-type calcium channels in cardiac and smooth muscle cells. By blocking these channels, it reduces the entry of calcium into the cells, leading to vasodilation of peripheral arteries and arterioles. This vasodilatory effect reduces peripheral resistance and, subsequently, lowers blood pressure.Â
Pharmacokinetics:Â
AbsorptionÂ
mibefradil was commonly given through oral administration, and its absorption from the gastrointestinal tract was known to be gradual and inconsistent. The rate of absorption could be influenced by the presence of food in the stomach.Â
DistributionÂ
After absorption, mibefradil would enter the bloodstream and be distributed throughout the body. It may bind to plasma proteins, which could influence its distribution to various tissues.Â
MetabolismÂ
mibefradil was primarily metabolized in the liver by the cytochrome P450 enzyme system, specifically CYP3A4. The major metabolite was hydroxy-mibefradil. The metabolism process could influence the drug’s efficacy and potential drug interactions.Â
Excretion and EliminationÂ
The metabolized mibefradil and its metabolites were excreted mainly through the feces (as metabolites) and to a lesser extent through the urine. The drug’s elimination half-life, which is the time it takes for half of the drug to be cleared from the body, could be influenced by its metabolism and excretion rates.Â
Administration: Â
mibefradil is typically administered orally in the form of tablets or capsules. The medication is usually taken with a glass of water, with or without food, as directed by the healthcare provider.Â
Patient information leafletÂ
Generic Name: mibefradilÂ
Why do we use mibefradil? Â
Hypertension: mibefradil was used to lower blood pressure by blocking calcium channels in the smooth muscles of blood vessels, leading to relaxation and dilation of the vessels, which helps in reducing blood pressure.Â
Chronic Stable Angina: mibefradil was employed in the treatment of chronic stable angina, By dilating the coronary arteries, mibefradil could increase blood supply to the heart and alleviate chest pain associated with angina.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
